SOURCE: MorphoSys AG

December 10, 2010 01:08 ET

Ad hoc:MorphoSys AG:Ad hoc: MorphoSys Increases Revenues and Operating Profit Guidance for 2010

MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwire - December 10, 2010) -

MorphoSys AG / / Ad hoc: MorphoSys Increases Revenues and Operating Profit Guidance for 2010 Processed and transmitted by Thomson Reuters.

The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today increased its financial guidance for 2010 mainly as a result of the achievement of revenues from additional commercial activities, resulting from the acquisition of Sloning BioTechnology GmbH in October 2010. MorphoSys now expects full-year revenues between EUR 91 million and EUR 94 million (from previously EUR 89 million to EUR 90 million). Correspondingly, the operating profit guidance is also increased, and expected to range between EUR 13 million and EUR 16 million (from previously EUR 7 million to EUR 9 million).

END OF AD HOC ANNOUNCEMENT


About MorphoSys:

MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM- CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visithttp://www.morphosys.com/



HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® are registered trademarks of MorphoSys.


This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.







Ad hoc Release (PDF): http://hugin.info/130295/R/1471128/407961.pdf




This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

[HUG#1471128]

Contact Information

  • For more information, please contact:
    MorphoSys AG
    Dr. Claudia Gutjahr-Loser
    Head of Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-122

    Mario Brkulj
    Senior Manager Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-454

    Jessica Kulpi
    Specialist Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-332

    Email Contact